Browse studies

Find your next paid study

8 recruiting studies matching your filters

An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) wh…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $8,750

Liquidia Technologies, Inc.NCT07759804

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of th…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07318597

Phase 2

A Phase 2A, Open-Label Single Arm Multicenter Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Doses of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH).

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial L…

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

Estimated

~$10 – $8,750

AllRock Bio, Inc.NCT07175038

Phase 2

A Phase II, Randomized, Double-Blind, Safety and Efficacy Study of Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus …

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $6,250

Stanford UniversityNCT07601295

Phase 1

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with P…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $7,500

Joseph C. WuNCT06872112

Phase 3

Remotely-Monitored Exercise to Enhance Functional Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Initiating Sotatercept Therapy: A Single-site Feasibility Study

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention p…

Pulmonary Arterial Hypertension (PAH)Exercise Therapy

Estimated

~$10 – $6,250

University of WashingtonNCT06941441

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the…

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension

Estimated

~$10 – $1,125

Franz Rischard, DONCT07487441

Rutgers University Study of the Genetics of Pulmonary Hypertension

The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligibl…

Pulmonary HypertensionPulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)+5 more

Estimated

~$10 – $750

Rutgers, The State University of New JerseyNCT07217522